Brain Navi's KrystoLens Single-Use Neuro-Endoscope Receives TFDA Certification for Taiwan Market Entry
核心洞察
Brain Navi Biotechnology (搜索)'s KrystoLens (搜索) single-use neuro-endoscope has received Taiwan Food and Drug Administration (搜索) certification, marking a key regulatory milestone for the medical device company.
The device is designed to reduce cross-infection risk, improve surgical ease of operation, and expand surgical field of view for minimally invasive neurosurgical procedures.
Brain Navi plans to launch a full-scale market push in Taiwan during the second half of 2026, working with medical institutions and distribution partners to accelerate clinical adoption.
Brain Navi Biotechnology (搜索) announced that its KrystoLens (搜索) single-use neuro-endoscope has officially received certification from the Taiwan Food and Drug Administration (搜索) (TFDA (搜索)), marking a significant regulatory milestone for the medical device company. The certification paves the way for the formal introduction of the innovative endoscopic solution into Taiwan's healthcare market.
Regulatory Achievement Following Innovation Recognition
The TFDA (搜索) certification comes after KrystoLens (搜索) gained recognition at the 22nd National Innovation Award earlier this year, highlighting both its product innovation and clinical potential. The regulatory approval confirms that the device complies with Taiwan's medical device requirements and represents a key step in the commercialization strategy for Brain Navi Biotechnology (搜索).
Clinical Design and Safety Features
KrystoLens (搜索) was developed with specific clinical needs in mind, focusing on addressing key challenges in neurosurgical procedures. The single-use neuro-endoscope is designed to help reduce the risk of cross-infection, improve ease of operation for surgeons, and expand the surgical field of view during procedures. Brain Navi Biotechnology (搜索) aims to provide medical institutions with a more efficient and flexible endoscopic solution through this technology.
Market Launch Strategy and Timeline
With growing demand for minimally invasive surgery and high-quality medical imaging, Brain Navi plans to begin a full-scale market push in Taiwan during the second half of 2026. The company will work closely with medical institutions, distribution partners, and clinical professionals to accelerate the adoption of KrystoLens (搜索) in clinical settings.
Brain Navi Biotechnology (搜索) stated that the TFDA (搜索) certification reflects the company's continued progress in research and development, quality management, and regulatory strategy. The achievement represents a crucial milestone in bringing the innovative medical imaging technology to healthcare providers.
International Expansion Plans
Brain Navi Biotechnology (搜索) plans to make Taiwan an important starting point for building clinical experience, expanding market presence, and supporting future international development. Through KrystoLens (搜索), the company aims to bring new possibilities to medical imaging technology and contribute to the growth of Taiwan's medical technology industry.
The successful regulatory approval positions Brain Navi to capitalize on the increasing adoption of minimally invasive surgical techniques and advanced medical imaging solutions in the neurosurgical field.